Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025
Bristol Myers Squibb's Opdivo and Yervoy Combination:
The Phase III CheckMate-8HW trial showed that combining Opdivo (nivolumab) with Yervoy (ipilimumab) significantly improved progression-free survival (PFS) in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)1.
The combination reduced the risk of death or disease progression by 38% compared to Opdivo monotherapy, with a p-value of 0.00031.
The overall response rate (ORR) was 71% for the combination versus 58% for Opdivo alone1.
Pfizer's Braftovi Regimen:
Pfizer's Braftovi (encorafenib), when used with cetuximab and the mFOLFOX6 chemotherapy regimen, showed significant ORR improvements in mCRC patients with the V600E mutation in the BRAF gene1.
The Braftovi combo yielded a 60.9% ORR, compared to 40% in counterparts who received chemotherapy with or without bevacizumab, with a p-value of 0.00081.
Median duration of response was 13.9 months in the Braftovi arm, compared to 11.1 months in control comparators1.
Survival Data:
Overall survival data for Pfizer's Braftovi regimen are still immature, but a trend in favor of the Braftovi combo was detected12.
Potential New Standards of Care:
The findings suggest that both BMS's Opdivo plus Yervoy and Pfizer's Braftovi regimen could become new standards of care for specific subtypes of metastatic colorectal cancer1.
Sources:
1. https://www.biospace.com/drug-development/bms-pfizer-challenge-colorectal-cancer-standard-care-with-asco-gi-readouts